Kyorin Pharmaceutical

[{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Kyorin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyorin Pharmaceutical \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Kyorin Pharmaceutical \/ Eisai"},{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Sumitomo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyorin And Sumitomo Pharma Enter Into License Agreement Of Vibegron In Taiwan And Other Asian Countries","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Kyorin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyorin Pharmaceutical \/ Sumitomo","highestDevelopmentStatusID":"12","companyTruncated":"Kyorin Pharmaceutical \/ Sumitomo"}]